What a great week for us CLLers. First FDA approval of idelalisib, then the positive recommendation for approval for idelalisib and ibrutinib in the EU, then the surprising FDA approval of ibrutinib in frontline 17p deleted patients. I will be parsing all this on my blog, but first I spent a quite a lot of time studying the indications and usage and speaking with experts on the new label for Idelalisib (or CAL-101 or GS-1101 or now Zydelig) and there are some subtle surprises in those details that I review in my blog.
I also included some links to the Gilead and LLS websites that provide details of what they offer in terms of their financial and other support.
If you are interested, please check out bkoffman.blogspot.com
We are all in this together